About us

is a new spin-off from the Research Institute of the Hospital de la Santa Creu i Sant Pau and Gendiag S.L., a Barcelona-based Biotechnology Company.


International leader in providing innovative solutions in the field of ischemic damage, ensuring excellent results for our customers and delivering value to shareholders.

To become a worldwide solution for reducing the ischemic damage after an acute myocardial infarction (AMI), ischemic stroke or transplanted organ by providing an innovative and breakthrough treatment through a process of innovation, research and development, driven by a desire to improve the quality of patients’ lives.